Argenx outlines upcoming earnings timetable, shares trade between key levels
Published on 06/22/2026 at 16:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Mark Bergmann, Earnings & Calendar desk. Reviewed prior to publication on 2026-06-22, 16:09.
Argenx (NL0010832176) has its next quarterly earnings call scheduled for 2026-07-23, giving investors a clear timetable for fresh numbers from the NASDAQ-listed biotech specialist. The session will update the market on commercial traction and pipeline progress in autoimmune diseases.
What the schedule shows
According to data compiled by TrendMatrix, Argenx is expected to report its next set of quarterly results and hold the associated earnings call on 2026-07-23, around 32 days from now. The company’s primary US listing trades under the ticker ARGX on NASDAQ, with additional trading in euros on European venues.
The same overview lists a current market capitalization of about 55.2 billion US dollars and a trailing price-earnings ratio close to 36, positioning Argenx among the larger names in the global biotechnology and medical research segment. These metrics underline that the upcoming earnings date is relevant well beyond its Euronext Brussels and NASDAQ investor base.
Analyst stance and expectations
Consensus data from TrendMatrix shows that 25 analysts actively cover Argenx, assigning an average rating equivalent to 4.2 out of 5, which corresponds to a broadly positive stance on the stock. The same source cites an average price target of 1,022 US dollars per share for the NASDAQ listing, above the last closing level of 877.72 dollars on 2026-06-18.
In a recent note highlighted by MarketScreener, RBC reiterated its Buy rating on Argenx, confirming the constructive tone of major research houses toward the shares even ahead of the July earnings event. For retail investors, the combination of a clearly dated earnings catalyst and a consistent analyst consensus provides a defined framework for the coming weeks.
All news and analysis on the Argenx shares
Further figures, ad-hoc announcements and historical price data on Argenx can be found in the dedicated topic area and in the company’s investor-relations section.
The business behind the ticker
Argenx generates its revenue primarily from efgartigimod, marketed as Vyvgart, a first-in-class FcRn antagonist approved for the treatment of generalized myasthenia gravis in adult patients in several major markets. The company is extending this antibody-fragment platform into additional autoimmune indications, aiming to build a diversified portfolio of targeted immunology therapies.
Where the shares trade today
The Argenx shares (NL0010832176) last closed on NASDAQ at 877.72 US dollars on 2026-06-18, while the parallel euro listing in the EURO STOXX 50 context shows around 772.00 euros on Finanzen100.
Key data on the Argenx shares
- Company: argenx SE
- ISIN: NL0010832176
- WKN: A11602
- Ticker: ARGX
- Trading venue: NASDAQ
- Price (as of 2026-06-18, 16:00): 877.72 USD
- Market cap: 55.2 billion USD (as of 2026-06-18)
- Sector / industry: Biotechnology / Medical research
- Index membership: EURO STOXX 50
- Next earnings date: 2026-07-23
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
